Infantile Epileptic Spasms (West Syndrome)
Infantile epileptic spasms syndrome (IESS), formerly known as West syndrome, is one of the most common and devastating epileptic encephalopathies of infancy, with an incidence of approximately 2–5 per 10,000 live births. The ILAE 2022 classification designates this condition as infantile epileptic spasms syndrome to emphasize the seizure type (epileptic spasms) rather than an eponymous label. The classic triad consists of epileptic spasms (brief tonic contractions of axial and proximal limb muscles, typically occurring in clusters), hypsarrhythmia on EEG, and developmental regression or plateau. IESS represents a neurologic emergency because the duration of spasms before effective treatment is the single most important modifiable predictor of neurodevelopmental outcome. Prompt diagnosis and initiation of first-line therapy—hormonal treatment (ACTH or high-dose prednisolone) or vigabatrin—is essential to maximize the chance of spasm cessation and neurodevelopmental recovery.
Bottom Line
- Clinical triad: Epileptic spasms in clusters (typically upon awakening), hypsarrhythmia on EEG, and developmental regression or stagnation; onset typically between 3 and 12 months of age
- Etiologies: Identified in approximately 60–70% of cases; structural (perinatal injury, cortical malformations, tuberous sclerosis), genetic (TSC1/TSC2, CDKL5, STXBP1, ARX, Trisomy 21), or metabolic causes; unknown etiology in 30–40%
- Treatment urgency: IESS is a neurologic emergency; treatment should be initiated within days of diagnosis; earlier treatment is associated with better neurodevelopmental outcomes
- First-line therapy: Hormonal therapy (ACTH or high-dose prednisolone) ± vigabatrin for most etiologies; vigabatrin is first-line for infantile spasms due to tuberous sclerosis complex (TSC)
- ICISS trial: Combination therapy (hormonal + vigabatrin) achieved spasm cessation in 72% versus 57% with hormonal therapy alone at day 14–42
- Long-term outcomes: Normal development in only 10–25% of cases overall; best outcomes in unknown etiology with rapid treatment response; 50–70% evolve to other epilepsy types, including Lennox-Gastaut syndrome
Epidemiology and Etiology
Incidence and Demographics
IESS affects approximately 2–5 per 10,000 live births, with a slight male predominance. The peak onset is between 4 and 7 months of age; onset before 3 months or after 12 months is uncommon and should prompt consideration of alternative diagnoses. The condition occurs worldwide with similar incidence across ethnic groups.
Etiologic Classification
The identification of an underlying etiology is critical for treatment selection, prognostic counseling, and genetic counseling. The ILAE classifies etiologies into structural, genetic, and metabolic categories:
| Etiologic Category | Proportion | Common Causes | Prognostic Implications |
|---|---|---|---|
| Structural | ~30–40% | Perinatal hypoxic-ischemic injury; malformations of cortical development (lissencephaly, polymicrogyria, focal cortical dysplasia); periventricular leukomalacia; cortical tubers (TSC); stroke; hemorrhage | Generally poorer neurodevelopmental outcome; epilepsy surgery may be an option for focal lesions |
| Genetic | ~15–25% | Trisomy 21; TSC1/TSC2 (tuberous sclerosis); CDKL5; STXBP1; ARX; KCNQ2; SCN2A; 1p36 deletion; many others identified on exome sequencing | Varies by gene; TSC patients respond preferentially to vigabatrin; some genetic etiologies have targeted treatments |
| Metabolic | ~5–10% | Pyridoxine-dependent epilepsy (ALDH7A1); biotinidase deficiency; mitochondrial disorders; aminoacidopathies; GLUT1 deficiency | Treatable metabolic causes represent a critical subset; pyridoxine trial should be considered in refractory cases |
| Unknown | ~30–40% | No identifiable structural, genetic, or metabolic cause despite comprehensive workup | Best prognosis overall if treatment response is prompt; formerly designated "cryptogenic" or "idiopathic" |
Diagnostic Workup
- EEG: Urgent EEG (ideally within 24–48 hours of suspected spasms) is mandatory; should include a sleep recording
- Brain MRI: Epilepsy protocol MRI to evaluate for structural causes; cortical tubers, malformations, and focal lesions guide treatment strategy
- Genetic testing: Exome sequencing (preferred) or epilepsy gene panel; chromosomal microarray if dysmorphic features or multiple anomalies are present
- Metabolic screening: Serum lactate, amino acids, urine organic acids; consider pyridoxine/pyridoxal phosphate trial in refractory cases
Clinical Features
Epileptic Spasms
Epileptic spasms are the defining seizure type and have distinct characteristics that differentiate them from other infantile paroxysmal events:
- Motor pattern: Brief (<1–2 seconds), symmetric, tonic contractions involving axial and proximal limb muscles; flexor spasms (trunk flexion, arm adduction) are most common, but extensor spasms (trunk and limb extension) and mixed flexor-extensor spasms also occur
- Clustering: Spasms characteristically occur in clusters of 5–30 or more, often immediately upon awakening from sleep or during drowsiness; clusters may last several minutes
- Subtle spasms: May consist only of brief eye deviation, a subtle head nod, or truncal flexion—easily missed by caregivers and clinicians
- Cry: A brief cry or fussiness frequently follows each spasm in the cluster
- Asymmetric spasms: Lateralized spasms (one side more involved than the other) suggest a focal structural lesion and warrant careful imaging evaluation for potential surgical candidacy
Hypsarrhythmia
Hypsarrhythmia is the hallmark interictal EEG pattern of IESS, though it is not universally present (approximately 60–70% of patients at diagnosis):
- Classic hypsarrhythmia: High-amplitude (>200 μV), disorganized, chaotic background with asynchronous, multifocal, high-voltage slow waves intermixed with spikes and sharp waves arising from all regions without consistent spatial or temporal organization
- Modified hypsarrhythmia: Variants include asymmetric hypsarrhythmia (suggesting a focal lesion), hypsarrhythmia with persistent focal discharges, or hypsarrhythmia with relative interhemispheric synchrony
- Ictal EEG: During a spasm, the EEG typically shows an electrodecremental response (sudden diffuse attenuation of background activity) lasting 1–2 seconds, often preceded by a high-amplitude generalized slow wave or sharp-slow wave complex
- Sleep: Hypsarrhythmia may be most prominent during NREM sleep and may fragment or become less chaotic during REM sleep
Recognizing Infantile Spasms Early
- Spasms can be mistaken for colic, startle responses, benign myoclonus of infancy, or gastroesophageal reflux; median delay from symptom onset to diagnosis is approximately 1 month
- Caregivers may describe the infant as "jackknifing" or "crunching"—particularly in clusters upon awakening
- Video of the events taken by caregivers is extremely valuable for diagnosis; encourage parents to record episodes
- Any infant with developmental regression or stagnation combined with clusters of brief symmetric movements should undergo urgent EEG
- A normal routine EEG does NOT rule out IESS if obtained only during wakefulness; sleep recording is essential
Developmental Regression
Developmental regression or plateau is the third component of the classic triad. Infants may lose previously acquired milestones (social smile, reaching, babbling) or fail to gain new skills. Loss of visual attention and social engagement is often the earliest and most distressing sign. The severity of regression is influenced by both the underlying etiology and the duration of uncontrolled spasms. Prompt treatment and spasm cessation may allow partial or complete developmental recovery, particularly in patients with unknown etiology.
Differential Diagnosis of Infantile Spasms
Several conditions can mimic infantile spasms and must be distinguished to avoid diagnostic delay or unnecessary treatment:
| Condition | Key Distinguishing Features | EEG |
|---|---|---|
| Benign myoclonus of infancy | Brief myoclonic jerks; normal development; no regression; self-resolving | Normal |
| Benign neonatal sleep myoclonus | Myoclonic jerks occurring exclusively during sleep; onset in first weeks of life; stops with arousal | Normal |
| Sandifer syndrome | Dystonic posturing associated with gastroesophageal reflux; arching of back and neck; related to feeding | Normal |
| Shuddering attacks | Brief trembling or shivering episodes; preserved consciousness; benign; may be a precursor to essential tremor | Normal |
| Hyperekplexia (startle disease) | Exaggerated startle response to tactile or auditory stimuli; stiffness; GLRA1 mutations; responsive to clonazepam | Normal |
| Early infantile DEE (non-spasm types) | Tonic or myoclonic seizures with burst suppression pattern; onset in first 3 months; different EEG signature | Burst suppression pattern (not hypsarrhythmia) |
| Myoclonic epilepsy in infancy | Generalized myoclonic seizures; normal development; not associated with hypsarrhythmia; typically self-limited | Generalized spike-and-wave; no hypsarrhythmia |
Late-Onset Spasms and Atypical Presentations
- Late-onset spasms (onset after 12–24 months) do occur but are uncommon; they may be associated with more severe underlying etiologies and carry a different differential diagnosis
- Spasms in children older than 2 years may overlap with the tonic seizures of Lennox-Gastaut syndrome; careful EEG distinction between hypsarrhythmia and slow spike-and-wave is important
- Epileptic spasms can recur in later childhood or even adulthood, sometimes after a seizure-free interval; these are often associated with cortical malformations
- "Subtle spasms" may present as brief eye deviations, grimacing, or head drops without obvious truncal flexion—video-EEG correlation is essential for diagnosis in ambiguous cases
Landmark Clinical Trials
| Trial | Design | Key Findings |
|---|---|---|
| UKISS (2004–2005) | Randomized; hormonal therapy (prednisolone or ACTH) vs. vigabatrin; 107 infants | Hormonal therapy was superior to vigabatrin for spasm cessation at day 14 (73% vs. 54%); exception: TSC-associated spasms responded better to vigabatrin; at 14 months, no difference in developmental outcomes between groups |
| UKISS long-term follow-up (2011) | Follow-up of UKISS cohort at ages 4 years | Children who received hormonal therapy initially had better developmental outcomes at age 4, particularly in the unknown-etiology group; led to hormonal therapy being recommended as first-line |
| ICISS (2017) | Randomized; hormonal therapy alone vs. hormonal therapy + vigabatrin; 377 infants across 5 countries | Combination therapy achieved spasm cessation in 72% vs. 57% with hormonal monotherapy (day 14–42); combination now recommended as first-line in many guidelines |
| ICISS 18-month follow-up (2018) | Follow-up of ICISS cohort at 18 months | No significant difference in developmental outcomes between groups at 18 months; however, children with spasm cessation had better outcomes regardless of treatment group, reinforcing the importance of achieving spasm control |
| EPISTOP (2021) | Randomized; preventive vigabatrin at first EEG abnormalities vs. standard treatment after clinical seizures in TSC infants | Preventive treatment reduced the risk and severity of epilepsy and improved developmental outcomes at 24 months; paradigm-shifting evidence for proactive EEG surveillance in TSC |
Treatment
First-Line Therapy
| Treatment | Regimen | Response Rate | Key Considerations |
|---|---|---|---|
| ACTH (high dose) | 150 IU/m2/day × 2–3 weeks, then taper over 2–4 weeks (US protocol); or 40–60 IU/day (natural ACTH) | ~65–75% spasm cessation | Most evidence-supported first-line; adverse effects include hypertension, irritability, immunosuppression, electrolyte disturbances, cardiomyopathy (rare); monitor BP, glucose, electrolytes |
| High-dose prednisolone | 40–60 mg/day (4 mg/kg/day) × 2–4 weeks, then taper | ~55–65% spasm cessation | Oral alternative to ACTH; UKISS trial showed similar efficacy to ACTH when given at high doses; better availability and lower cost than ACTH in some countries |
| Vigabatrin | 100–150 mg/kg/day in 2 divided doses; may increase to 200 mg/kg/day | ~35–50% overall; ~65–95% in TSC | First-line for TSC-associated IESS; irreversible visual field constriction (25–50% with prolonged use); limit duration to 6 months if possible; less effective for non-TSC etiologies as monotherapy |
| Combination (hormonal + vigabatrin) | Hormonal therapy + vigabatrin simultaneously | ~72% spasm cessation (ICISS trial) | ICISS trial demonstrated superiority of combination over hormonal monotherapy; increasingly recommended as first-line in many guidelines |
Treatment Urgency and Monitoring
- Time is brain: Treatment should be initiated as soon as the diagnosis is confirmed; delays of even 1–2 weeks are associated with worse neurodevelopmental outcomes
- Treatment response assessment: Clinical response (cessation of spasms) should be evaluated at 2 weeks; EEG should be repeated at 2–4 weeks to confirm resolution of hypsarrhythmia
- ACTH monitoring: Blood pressure (at least daily during induction), serum glucose, electrolytes, urinalysis; families must be educated about immunosuppression and infection risk; avoid live vaccines during treatment
- Vigabatrin monitoring: Baseline visual assessment (ERG or VEP where feasible); visual field testing at 3–6 months and periodically thereafter; limit treatment duration to minimize retinal toxicity
- Relapse: Spasm relapse occurs in approximately 15–30% of initial responders; retreatment with the initially effective agent is usually recommended
Second-Line and Adjunctive Therapies
When first-line treatment fails, the following options may be considered:
- Ketogenic diet: Effective in approximately 50–60% of patients with refractory IESS; should be initiated under the guidance of a ketogenic diet team; particularly beneficial in patients with GLUT1 deficiency or metabolic etiologies
- Topiramate: Some evidence for adjunctive use; mechanism includes carbonic anhydrase inhibition and AMPA/kainate receptor blockade
- Pyridoxine (vitamin B6): High-dose pyridoxine (30–50 mg/kg/day) is effective in a subset of patients, particularly those with pyridoxine-dependent epilepsy; a pyridoxine trial is recommended in refractory cases or when metabolic etiology is suspected
- Valproate: May be used as adjunctive therapy but is generally considered less effective than ACTH or vigabatrin for IESS
- Epilepsy surgery: For infants with focal structural lesions (focal cortical dysplasia, single dominant tuber, hemispheric malformation); early surgical evaluation is critical in treatment-refractory cases with a potentially resectable lesion
Evolution and Long-Term Outcomes
Evolution to Other Epilepsy Types
IESS evolves to other forms of epilepsy in approximately 50–70% of cases:
- Lennox-Gastaut syndrome (LGS): The most common evolution, occurring in approximately 20–40% of patients; characterized by multiple seizure types (tonic, atonic, atypical absence), slow spike-and-wave on EEG, and cognitive impairment
- Focal epilepsy: Patients with underlying focal structural lesions may develop focal seizures as spasms resolve
- Other developmental and epileptic encephalopathies: Some children develop drug-resistant mixed epilepsies without meeting formal criteria for LGS
- Seizure resolution: A minority of patients, particularly those with unknown etiology and prompt treatment response, achieve seizure freedom
Neurodevelopmental Outcomes
| Prognostic Factor | Favorable | Unfavorable |
|---|---|---|
| Etiology | Unknown ("cryptogenic"); no underlying structural or genetic cause | Structural brain lesion; severe genetic etiology (e.g., lissencephaly, large TSC burden) |
| Development before spasms | Normal development prior to onset | Pre-existing developmental delay or regression |
| Treatment response | Rapid cessation of spasms (<2 weeks) with resolution of hypsarrhythmia | Persistent spasms despite treatment; hypsarrhythmia not resolved |
| Treatment latency | Short lead time (diagnosis to treatment <1 month) | Prolonged lead time (>1 month from symptom onset to treatment) |
| Age of onset | Later onset (closer to 12 months) | Very early onset (<3 months; consider early infantile DEE) |
| Relapse | No relapse after initial treatment | Multiple relapses; evolution to LGS |
Overall, approximately 10–25% of children with IESS achieve normal or near-normal cognitive development, with the best outcomes in the unknown-etiology group with rapid treatment response. Intellectual disability (moderate to severe) occurs in 70–80% of cases overall. Mortality is approximately 5–10% in the first 3 years, primarily related to the underlying etiology rather than the spasms themselves.
Key Messages for Clinicians
- Maintain a high index of suspicion for infantile spasms in any infant with developmental regression or new-onset clusters of brief symmetric movements
- Expedite EEG (including sleep recording) and brain MRI when IESS is suspected
- Initiate treatment immediately upon diagnosis—do not wait for the complete etiologic workup; the etiologic evaluation can proceed in parallel with treatment
- For TSC-associated IESS, vigabatrin is first-line; for all other etiologies, hormonal therapy (ACTH or high-dose prednisolone) ± vigabatrin is preferred
- Follow-up EEG at 2–4 weeks is mandatory to assess treatment response (resolution of hypsarrhythmia)
- Early referral for epilepsy surgery evaluation in patients with treatment-refractory IESS and a potentially resectable focal lesion can be transformative
References
- Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1349–1397.
- Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005;4(11):712–717.
- O'Callaghan FJ, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol 2017;16(1):33–42.
- O'Callaghan FJ, Edwards SW, Alber FD, et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health 2018;2(10):715–725.
- Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev 2013;(6):CD001770.
- Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2012;78(24):1974–1980.
- Pavone P, Polizzi A, Marino SD, et al. West syndrome: a comprehensive review. Neurol Sci 2020;41(12):3547–3562.
- Kossoff EH, Hartman AL, Rubenstein JE, Vining EP. High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH. Epilepsy Behav 2009;14(4):674–676.
- Riikonen R. Long-term outcome of patients with West syndrome. Brain Dev 2001;23(7):683–687.
- Caraballo RH, Fortini S, Reyes G, et al. Epileptic spasms in clusters with focal EEG paroxysms: a study of 12 patients. Seizure 2016;35:88–92.
- Specchio N, Curatolo P. Developmental and epileptic encephalopathies: what we do and do not know. Brain 2021;144(1):32–43.